Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Okamoto, Shinya ^a   Jiang, Yuanyuan ^b,c   Kawamura, Kiyoko ^b   Shingyoji, Masato ^b   Fukamachi, Toshihiko ^a   Tada, Yuji ^c   Takiguchi, Yuichi ^c   Tatsumi, Koichiro ^c   Shimada, Hideaki ^d   Hiroshima, Kenzo ^e   Kobayashi, Hiroshi ^a   Tagawa, Masatoshi ^b,c  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; PROTEIN P53; SMALL INTERFERING RNA; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MESOTHELIOMA; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84875548802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060297     Document Type: Article

References (31)

1. Tada Y, Takiguchi Y, Hiroshima K, Hiroshima K, Shimada H, et al. (2008) Gene therapy for malignant pleural mesothelioma: Present and Future. Oncol Res 17: 239-246.
2. Robinson BWS, Lake RA, (2005) Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603.
3. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, et al. (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE 6: e18828 doi:10.1371/journal.pone.0018828.
4. Prins JB, Williamson KA, Kamp MMK, Van Hezink EJ, Van Der Kwast TH, et al. (1998) The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75: 649-653.
5. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, et al. (2009) Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesothelioma from Arf knockout mice. Proc Natl Acad Sci USA 106: 3420-3425.
6. Robinson BWS, Musk AW, Lake RA, (2005) Malignant mesothelioma. Lancet 366: 397-408.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
8. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T, (2007) Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 14: 2126-2135.
9. Green JR, (2003) Antitumor effects of bisphosphonates. Cancer 97 (Suppl 3):: 840-847.
10. Green JR, (2004) Bisphosphonates: preclinical review. Oncologist 9 (Suppl 4):: 3-13.
11. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr, et al. (2003) The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 43: 154-162.
12. Clézardin P, (2011) Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71-79.
13. Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, et al. (2006) Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 97: 183-191.
14. Yang CT, You L, Yeh CC, Chang JWC, Zhang F, et al. (2000) Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. Natl Cancer Inst 92: 636-641.
15. Kim WY, Sharpless NE, (2006) The regulation of INK4/ARF in cancer and aging. Cell 127: 265-275.
16. Hoskins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, et al. (2006) p53-induced apoptosis occurs in the absence of p14ARF in malignant pleural mesothelioma. Neoplasia 8: 551-559.
17. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, et al. (2004) p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 95: 186-192.
18. Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, et al. (2007) Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71: 333-343.
19. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
20. Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, et al. (2007) Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 250: 194-205.
21. Li Q, Kawamura K, Okamoto S, Yamanaka M, Yang S, et al. (2012) Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19: 218-228.
22. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, et al. (2007) p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 6: 1478-1482.
23. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, et al. (2012) Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 30: 1692-1698.
24. Horie H, Murata H, Kimura S, Takeshita H, Sakabe T, et al. (2007) Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Brit J Cancer 96: 255-261.
25. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, et al. (2003) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102: 2229-2235.
26. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, et al. (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178.
27. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
28. Liu DH, Liu WC, Fan Li, Sheng R, Xue Y, et al. (2006) Clinical effect of p53 gene Gendicine in treatment. Chin J Cancer Prev Treat 13: 1108-1109.
29. Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA, et al. (2000) Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther 7: 537-544.
30. Weinrib L, Li JH, Donovan J, Huang D, Liu FF, (2001) Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and-negative nasopharyngeal carcinoma. Cancer Gene Ther 8: 352-360.
31. Bar-Sagi D, Hall A, (2000) Ras and Rho GTPases: a family reunion. Cell 103: 227-238.